This article first appeared on GuruFocus.

Treace Medical Concepts Inc (NASDAQ:TMCI) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $49.73 million, and the earnings are expected to come in at -$0.28 per share. The full year 2025's revenue is expected to be $227.08 million and the earnings are expected to be -$0.81 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 4 Warning Signs with TMCI.

Is TMCI fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Treace Medical Concepts Inc (NASDAQ:TMCI) have increased from $227.03 million to $227.08 million for the full year 2025 and declined from $250.67 million to $248.49 million for 2026 over the past 90 days. Earnings estimates have declined from -$0.80 per share to -$0.81 per share for the full year 2025 and declined from -$0.70 per share to -$0.72 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Treace Medical Concepts Inc's (NASDAQ:TMCI) actual revenue was $47.39 million, which beat analysts' revenue expectations of $47.05 million by 0.71%. Treace Medical Concepts Inc's (NASDAQ:TMCI) actual earnings were -$0.28 per share, which beat analysts' earnings expectations of -$0.29 per share by 2.78%. After releasing the results, Treace Medical Concepts Inc (NASDAQ:TMCI) was up by 7.92% in one day.

Based on the one-year price targets offered by 5 analysts, the average target price for Treace Medical Concepts Inc (NASDAQ:TMCI) is $8.50 with a high estimate of $12.00 and a low estimate of $6.00. The average target implies an upside of 31.38% from the current price of $6.47.

Based on GuruFocus estimates, the estimated GF Value for Treace Medical Concepts Inc (NASDAQ:TMCI) in one year is $14.48, suggesting an upside of 123.80% from the current price of $6.47.

Based on the consensus recommendation from 6 brokerage firms, Treace Medical Concepts Inc's (NASDAQ:TMCI) average brokerage recommendation is currently 2.5, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.